Drs. Gurram and Yerram conclude with a discussion on the importance of multidisciplinary care for hereditary kidney cancer.
Renal Cell Carcinoma
Latest News
Drs. Gurram and Yerram review options for hereditary kidney cancers, highlight data on bevacizumab plus erlotinib, anlotinib.
Researchers aimed to validate the use of the GRANT score to predict the prognosis of patients with pRCC after surgery.
New data on long-term outcomes from phase 3 of KEYNOTE-426 included efficacy and prespecified exploratory biomarker analyses.
Researchers sought to understand the benefits of combining IO and targeted therapies for treating nccRCC in patients.
Drs. Gurram, Yerram examine the clinical features and aggressive behavior of FH-deficient renal cell carcinoma and more.
Drs. Gurram, Yerram provide an overview of hereditary vs sporadic kidney cancer and highlight key syndromes like VHL, HLRCC.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
At the Oncology Forum, Dr. Sanjay Juneja led a dynamic discussion covering pivotal developments across genitourinary cancers.
Dr. Loïc Djaileb explores the use of RECIP 1.0 criteria with SPECT/CT and the efficacy of this strategy in monitoring mCRPC.
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
Trending
Drs. Gurram and Yerram review options for hereditary kidney cancers, highlight data on bevacizumab plus erlotinib, anlotinib.
Researchers aimed to validate the use of the GRANT score to predict the prognosis of patients with pRCC after surgery.
New data on long-term outcomes from phase 3 of KEYNOTE-426 included efficacy and prespecified exploratory biomarker analyses.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.